Regarding the potential practical application of the current findings in precision medicine, our data suggest that, based on the STR somatic mutation status of BRAF and APC in the BCC tumor tissue, it may be possible to select a group of patients who may respond well to some of the targeted therapy. This evidence concerns the gene BRAF and neoplasm.